Huaier Trametes
Huaier Trametes
Huaeier Trametes is obtained from the Huaeier mushroom.
The Huaier mushroom, also known as "Trametes versicolor" or "Coriolus versicolor", is a mushroom found in various parts of the world and has long been used in traditional Chinese medicine and other Asian cultures. It is also called "Butterfly Stramete" or "Turkish Hat" due to its striking appearance with butterfly-like colors and patterns on its surface.
In traditional medicine, Huaier mushroom is often used to strengthen the immune system and treat various health problems. It contains various bioactive compounds, including polysaccharides and proteins, which are considered to have potential health benefits.
Studies have already been conducted suggesting that Huaier mushroom may have antioxidant, immunomodulatory and anti-inflammatory properties.
The effect of Huaier against cancer and vaccination spikes
The first study involved 8 people whose stage 4 cancer was cured by Huaier. The vaccination led to a new flare-up of cancer and death within a very short time in participants who did not take the Huaier. There were no changes and no problems in the patients who continued taking Huaier.
The researchers located the problems with serial vaccinations in the destructive effects on the molecular mechanisms of protein synthesis through the destruction of ribosomal RNA structures. The enzymes without which life is not possible are produced in these central structures of the cell, the ribosomes. Their destruction or disability results in death. Before this study, no one had realized that vaccine damage occurs through spike penetration into this deepest level of cells.
A follow-up study is entitled “Huaier Effects on Prevention and Inhibition of Spontaneous SARS-CoV-2 Virion Production by Repeated Pfizer-BioNTech mRNA Vaccination“ and deals with the further elucidation of the harmful mechanisms of the vaccination spike and how the protection provided by the fungi functions.
“As part of our clinical research, we observed and reported spontaneous production of SARS-CoV-2 virions and virion parts following the Pfizer-BioNTech mRNA vaccination, which occurred starting 3 weeks after the first injection. Significant disruption of ribosomal RNA structures was also noted, which was enhanced by repeated vaccinations. The aim of the present study is to define the molecular mechanisms for the production of SARS-CoV-2 virions after injection of the mRNA vaccination and to compare them with virion proliferation in unvaccinated patients with severe COVID-19 pneumonia and fibrosis.”
The methods described are:
“We are conducting clinical research to define the molecular basis for the significant anti-cancer activity of Huaier (Trametes robiniophila murr). In the present study, we used peripheral blood samples from volunteer patients suspected of having lung cancer by CT image analysis and age-matched normal controls with or without Huaier administration. Molecular characterization was performed by sequencing total RNA and non-coding small RNA on the BGISEQ-500 platform (approximately 7.0 GB of analysis per sample).”
The Huaier mushroom also appears to be effective against cancer:
Minghao Wang et al.
investigated the use of Huaier granules in the postoperative treatment of triple-negative breast cancer in a clinical trial.
Background:
In recent years, traditional Chinese medicine (TCM) has been developing rapidly in cancer treatment. Huaier is a widely used fungus by TCM to treat different kinds of cancers. Its good efficacy in prevention of tumor recurrence and metastasis has been proven by a large number of clinical studies. In order to further investigate the efficacy and safety of Huaier granules in post-surgical therapy for stage I–III triple-negative breast cancer (TNBC) patients, we performed a case-control clinical study to observe its effects on the post-surgical safety and survival rates of these patients.
Methods:
Two hundred and one TNBC patients underwent modified radical mastectomy were selected, they were admitted to our hospital between October 2010 to September 2014. The patients were randomly allocated to the experimental group (101 cases) or the control group (100 cases). Patients in the experimental group were treated with Huaier granules, by orally taking 20 g each time with 3 times a day. Medication was started during chemotherapy or at the time in 6 or 18 months after it. The control group did not receive
any TCM preparations during this process. The disease-free survival (DFS) and overall survival (OS) were measured as the main outcome.
Results:
The median follow-up time was 46 months. For the 100 patients in control group, 5-year DFS and OS was 82% and 86% respectively, while 87.1% and 90.1% for the 101 patients in the experimental group. The difference was not statistically significant. However, stage III patients in the control group showed a 5-year DFS of 53.8% and OS of 65.4%, which were significantly lower than that of stage III patients in the experimental group as 81.3% and 87.5%. In the experimental group, 10 patients with 6-month medication showed disease progression, whereas only 3 patients with 18-month medication showed disease progression. This difference was statistically significant as well.
Conclusions:
Huaier granules could play an important role in post-surgical adjuvant therapy of TNBC patients, specially by effectively increasing the DFS and OS of breast cancer patients at middle to advanced stage.
Studies are currently underway at the University of Fudan (China). Aim of the study is the effect of Huaier Granules in Reducing Tumor Marker Levels in Patients With Early Stage Breast Cancer
.
.